Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL

Bookmark and Share
Published: 18 Dec 2019
Views: 202
Rating:
Save
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Prof Constantine Tam speaks to ecancer at the 2019 ASH meeting in Orlando about the safety and efficacy of the novel BTK inhibitor zanubrutinib.

He reports that this agent has a more favourable safety profile compared to ibrutinib, due to its specificity.

Prof Tam describes the phase III SEQUOIA trial investigating zanubrutinib in chronic lymphocytic leukaemia (CLL) patients with a 17p deletion and reports that this group of patients had a high response rate of 92.7 percent.



 

Related Videos

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in...
Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switz...
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans ( Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland )
19 Dec 2019
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT afte...
Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )
19 Dec 2019
Outcomes in patients with therapy-Related AML who achieved remission with CPX-35...
Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, US...
Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
19 Dec 2019
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML tr...
Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
18 Dec 2019
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from ...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzu...
Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene...
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL ( Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene, USA )
17 Dec 2019
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell l...
Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma ( Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA )
17 Dec 2019
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory c...
Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia ( Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center )
17 Dec 2019
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
13 Dec 2019